ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Science 37 Named Finalist in Two Categories for the 2026 SCOPE Awards

MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE Awards: the Participant Engagement Award and the Site Innovation Award. This marks the first time that a single company has been named a finalist for two SCOPE Award categories in the same year.

Driving Engagement Through Community Pharmacies

Science 37 was recognized for the Participant Engagement Award for its “Pharm-to-Trial” partnership with RxE2. This decentralized vaccine trial model brings research to agricultural U.S. communities by utilizing local pharmacies as trusted access points.

Supported by Science 37’s research-grade nurses and board-certified investigators, this "hub-and-spoke" model removes socioeconomic barriers and leverages local healthcare relationships to improve diversity and data quality.

Redefining the Clinical Trial Site

The nomination for the Site Innovation Award honors Science 37’s Direct-to-Patient Clinical Trial Site, which enables participation directly from patients’ homes. With nationwide reach supported by 50-state medical licensure, the site expands access beyond traditional site boundaries and accelerates enrollment for clinical trial sponsors.

“These nominations reflect our commitment to expanding patient access while delivering operational excellence,” said Tyler Van Horn, Chief Executive Officer of Science 37. “Being the first company recognized in two categories simultaneously is a testament to our team's dedication to making research more accessible and inclusive.”

Final judging will take place at the SCOPE Summit in Orlando, Florida, February 2–5, 2026.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
PR@science37.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.18
+1.53 (0.65%)
AAPL  258.37
-1.59 (-0.61%)
AMD  227.92
+4.32 (1.93%)
BAC  52.59
+0.11 (0.21%)
GOOG  333.16
-3.15 (-0.94%)
META  620.80
+5.28 (0.86%)
MSFT  456.66
-2.72 (-0.59%)
NVDA  187.05
+3.91 (2.13%)
ORCL  189.85
-3.76 (-1.94%)
TSLA  438.57
-0.63 (-0.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.